Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Glioblastoma 4Pancreatic Neoplasms 3Multiple Myeloma 3Neoplasms 2Glioma 2Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Polycystic Ovary Syndrome 1Oligodendroglioma 1Obesity 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Gliosarcoma 1Colorectal Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 17Dexamethasone 15Bortezomib 14fludarabine phosphate 12Melphalan 12Lenalidomide 10fludarabine 9Filgrastim 8pomalidomide 7Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Rituximab 6Radiotherapy 6Etoposide 6Whole-Body Irradiation 5Cord Blood Stem Cell Transplantation 5Calcium Dobesilate 5Busulfan 5Antilymphocyte Serum 5sargramostim 4Sirolimus 4Panobinostat 4Mycophenolic Acid 4Methylprednisolone 4Cyclosporine 4carfilzomib 3Vorinostat 3Stem Cell Transplantation 3Prednisone 3Methotrexate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Plasma Cell × Ascorbic Acid × Clear all
NCT00258245 2013-04-29

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
5 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡